首页 工具
登录
购物车
SKL2001

SKL2001

产品编号 T6989   CAS 909089-13-0

SKL2001 是一种Wnt/β-catenin 信号通路的激动剂,具有抗肿瘤作用。它能够破坏 Axin/β-catenin 相互作用,稳定细胞内 β-catenin。

TargetMol的所有产品和服务仅用于科学研究,不能被用于人体,我们也不向个人提供产品和服务。
SKL2001 Chemical Structure
SKL2001, CAS 909089-13-0
规格 价格/CNY 货期 数量
1 mg ¥ 152 现货
5 mg ¥ 339 现货
10 mg ¥ 547 现货
25 mg ¥ 1,130 现货
50 mg ¥ 1,970 现货
100 mg ¥ 3,580 现货
200 mg ¥ 5,250 现货
500 mg ¥ 7,960 现货
1 mL * 10 mM (in DMSO) ¥ 593 现货
产品目录号及名称: SKL2001 (T6989)
点击图片重新获取验证码
选择批次  
纯度: 99.5%
纯度: 97.90%
更多批次查询请联系客服
生物活性
化学信息
存储 & 溶解度
参考文献
产品描述 SKL2001, an agonist of the Wnt/β-catenin pathway, can disrupt the Axin/β-catenin interaction.
体外活性 SKL2001 upregulated β-catenin responsive transcription by increasing the intracellular β-catenin protein level and inhibited the phosphorylation of β-catenin at residues Ser33/37/Thr41 and Ser45, which would mark it for proteasomal degradation, without affecting CK1 and GSK-3β enzyme activities. SKL2001 disrupted the Axin/β-catenin interaction, which is a critical step for CK1- and GSK-3β-mediated phosphorylation of β-catenin at Ser33/37/Thr41 and Ser45. The treatment of mesenchymal stem cells with SKL2001 promoted osteoblastogenesis and suppressed adipocyte differentiation, both of which were accompanied by the activation of Wnt/β-catenin pathway. SKL2001 did not affect either NF-κB or p53 reporter activity and inhibits β-catenin phosphorylation without affecting GSK-3β activity[1].
细胞实验 The HEK293 reporter and control cell lines were established. The HEK293 reporter cells were inoculated into 384-well plates at 10 000 cells per well and grown for 24 h. Next, each compound in the chemical library (~270 000) was added to at a final concentration of 20 μM. After 15 h, the plates were assayed for firefly luciferase activity.(Only for Reference)
分子量 286.29
分子式 C14H14N4O3
CAS No. 909089-13-0

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

DMSO: 53 mg/mL (185.1 mM)

Ethanol: 53 mg/mL (185.1 mM)

H2O: < 1 mg/mL (insoluble or slightly soluble)

溶液配制表

可选溶剂 浓度 体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO / Ethanol 1 mM 3.493 mL 17.4648 mL 34.9296 mL 87.324 mL
5 mM 0.6986 mL 3.493 mL 6.9859 mL 17.4648 mL
10 mM 0.3493 mL 1.7465 mL 3.493 mL 8.7324 mL
20 mM 0.1746 mL 0.8732 mL 1.7465 mL 4.3662 mL
50 mM 0.0699 mL 0.3493 mL 0.6986 mL 1.7465 mL
100 mM 0.0349 mL 0.1746 mL 0.3493 mL 0.8732 mL

计算器

摩尔浓度计算器
稀释计算器
配液计算器
分子量计算器
=
X
X
X
=
X
=
/
g/mol

输入分子式,点击计算,可计算出产品的分子量。

参考文献

1. Gwak J, et al. Cell Res. 2012, 22(1):237-47. 2. Lu F, Sun X, Xu X, et al. SILAC-based proteomic profiling of the suppression of TGF-β1-induced lung fibroblast-to-myofibroblast differentiation by trehalose[J]. Toxicology and Applied Pharmacology. 2020, 391: 114916. 3. Lu F, Sun X, Xu X, et al. SILAC-based proteomic profiling of the suppression of TGF-β1-induced lung fibroblast-to-myofibroblast differentiation by trehalose[J]. Toxicology and Applied Pharmacology. 2020: 114916.

文献引用

1. Liu X, Xie P, Hao N, et al. HIF-1–regulated expression of calreticulin promotes breast tumorigenesis and progression through Wnt/β-catenin pathway activation. Proceedings of the National Academy of Sciences. 2021, 118(44) 2. Cheng X, Qin L, Deng L, et al. SNX-2112 Induces Apoptosis and Inhibits Proliferation, Invasion, and Migration of Non-Small Cell Lung Cancer by Downregulating Epithelial-Mesenchymal Transition via the Wnt/β-Catenin Signaling Pathway. Journal of Cancer. 2021, 12(19): 5825-5837. 3. Lu F, Sun X, Xu X, et al. SILAC-based proteomic profiling of the suppression of TGF-β1-induced lung fibroblast-to-myofibroblast differentiation by trehalose. Toxicology and Applied Pharmacology. 2020: 114916 4. Yan Z, Ruan B, Wang S, et al.RNA-binding Protein QKI Inhibits Osteogenic Differentiation Via Suppressing Wnt Pathway.Archives of Medical Research.2023: 102853.
Hematein β-catenin/CBP-IN-1 DK419 9-Hydroxycanthin-6-one iCRT-5 NCB-0846 WIKI4 MN-64

相关化合物库

该产品包含在如下化合物库中:
NO PAINS 化合物库 抗前列腺癌化合物库 Wnt/Hedgehog/Notch 通路化合物库 抗衰老化合物库 抗纤维化化合物库 抗癌活性化合物库 已知活性化合物库 成骨分子库 抗结直肠癌化合物库 抗肺癌化合物库

剂量换算

对于不同动物的给药剂量换算,您也可以参考 更多...

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。

第一步:请输入动物实验的基本信息
剂量
mg/kg
每只动物体重
g
给药体积
μL
动物数量
第二步:请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% ddH2O
计算 重置

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

SKL2001 909089-13-0 Cytoskeletal Signaling Stem Cells Wnt/beta-catenin Inhibitor Wnt Beta catenin β-catenin SKL-2001 inhibit SKL 2001 inhibitor

 

陶术
生物
TargetMol®中国区唯一合作伙伴
点击进入陶术生物官网陶术生物
联系我们
400-820-0310

上海市静安区江场三路238号8楼